ampelopsin has been researched along with Liver Dysfunction in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, P; Ji, G; Wang, J; Wang, Y; Wu, T; Xiang, H | 1 |
| Bi, Y; Chen, J; Fu, J; Liu, B; Wang, X; Xia, T; Zhu, R | 1 |
| Chen, J; Chen, Y; Chi, X; Guo, D; Jiang, Y; Jiang, Z; Lin, J; Lv, L; Pi, H; Qin, W; Yang, H | 1 |
2 review(s) available for ampelopsin and Liver Dysfunction
| Article | Year |
|---|---|
Recent update on application of dihydromyricetin in metabolic related diseases.
Topics: AMP-Activated Protein Kinases; Anti-Inflammatory Agents; Antioxidants; Cell Death; Flavonols; Glucose; Humans; Lipid Metabolism; Liver Diseases; Metabolic Diseases; MicroRNAs; Neoplasms; Oxidative Stress; Peroxisome Proliferator-Activated Receptors; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction | 2022 |
Molecular mechanisms and therapeutic implications of dihydromyricetin in liver disease.
Topics: Carcinoma, Hepatocellular; Flavonols; Humans; Liver Diseases; Liver Diseases, Alcoholic; Liver Failure, Acute; Liver Neoplasms; Liver Regeneration; Non-alcoholic Fatty Liver Disease; Protective Agents | 2021 |
1 other study(ies) available for ampelopsin and Liver Dysfunction
| Article | Year |
|---|---|
Dihydromyricetin protects against liver ischemia/reperfusion induced apoptosis via activation of FOXO3a-mediated autophagy.
Topics: Animals; Apoptosis; Autophagy; Caspase 3; Disease Models, Animal; Flavonols; Forkhead Box Protein O3; Liver Diseases; Mice; Mice, Inbred C57BL; Phosphorylation; Protective Agents; Reperfusion Injury | 2016 |